Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials

Sylvester, Richard; Meijden, A.P.M. van der; Oosterlinck, Willem; Witjes, J. Alfred; Bouffioux, C; Denis, L.; Newling, D. W. W.; Kurth, K. H.

doi:10.1016/j.eururo.2005.12.031

Cited by 2,515 publications

(2,094 citation statements)

References 49 publications

Supporting

Mentioning

1,828

Contrasting

Unclassified

Order By: Relevance

“…The probability of progression at 5 years in T1G3 patients with and without CIS is 74% and 29%, respectively; however, in patients with T1G2 and CIS, the risk is about 17%. 22 In the present study, the incidence of CIS in patients with T1G2 tumors was 8.5%, and the rate of progression was 3.4% in those without concomitant CIS compared with 13.2% in those with it (P ϭ 0.001).…”

Section: Commentsupporting

confidence: 41%

“…A subset of 41 patients with Stage T1G2 were studied, with 32% showing tumor progression and 22% dying of the disease. 21 Using the European Organization for Research and Treatment of Cancer risk tables reported by Sylvester et al, 22 which allow the calculation of short-and long-term risk of recurrence and progression in patients with Stage Ta-T1 bladder cancer, a patient with a primary solitary or multiple T1G2 bladder tumor has a probability of progression at 5 years ranging of 6%-17%.…”

Section: Commentmentioning

confidence: 99%

See 1 more Smart Citation

Recurrence at Three Months and High-grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors

Palou

Rodríguez-Rubio

Millán

et al. 2009

Urology

View full text Add to dashboard Cite

OBJECTIVESTo evaluate the risk factors for disease progression in the frequent subgroup of Stage T1G2 (World Health Organization 1973) bladder tumors using an analysis of a large cohort of patients with Stage T1G2 disease. METHODSA cohort of 616 patients with Stage T1G2 were treated with transurethral resection and random bladder biopsies. The mean follow-up was 4.2 years. Univariate and multivariate analyses were done using Cox regression analysis. The independent variables were multiplicity, association with carcinoma in situ (CIS), tumor size, tumor recurrence at 3 or 6 months, tumor grade, and association with CIS at first recurrence. The dependent variable was progression to muscleinvasive disease. RESULTSProgression to muscle-invasive disease was identified in 28 of the 616 patients (4.5%). On multivariate analysis, when considering recurrence at 3 months, this factor was the principal prognostic factor, with a relative risk of 4.0 (95% confidence interval 1.2-13.3), followed by the presence of high-grade disease or CIS at first recurrence (relative risk 2.8, 95% confidence interval 1.3-5.8) and CIS associated with the primary tumor (relative risk 1.8, 95% confidence interval 1.1-2.9). When considering recurrence at 6 months, more prognostic factors were involved for progression, including as multiple tumors, CIS associated with the primary tumor, recurrence at 6 months, and the presence of high-grade disease or CIS at the first recurrence. CONCLUSIONSIn primary urothelial T1G2 bladder cancer, recurrence at 3 months was the main prognostic factor related to progression. Additional factors were the association of CIS with the primary tumor and the presence of high-grade disease and/or CIS at first recurrence. UROLOGY 73: 1313UROLOGY 73: -1317UROLOGY 73: , 2009

show abstract

Section: Commentsupporting

confidence: 41%

Section: Commentmentioning

confidence: 99%

Recurrence at Three Months and High-grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors

Palou

Rodríguez-Rubio

Millán

et al. 2009

Urology

View full text Add to dashboard Cite

show abstract

“…Tumor behavior can be hard to determine from histopathology alone. For example, the progression risk for non-muscle UCC varies between <1% and >50% [1,2]. Furthermore, as stage and grade are often linked, when one is fixed (e.g.…”

Section: Introductionmentioning

confidence: 99%

The Application of Artificial Intelligence to Microarray Data: Identification of a Novel Gene Signature to Identify Bladder Cancer Progression

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Further treatment depends on the patient's risk of recurrence and progression to muscle-invasive disease [2]. In patients at low risk of recurrence and progression, no further treatment is recommended prior to a subsequent recurrence.…”

Section: Introductionmentioning

confidence: 99%

“…The remaining patients have an intermediate risk of progression and an intermediate to high risk of recurrence, with the risk of recurrence depending, to a large extent, on the number of tumors [2]. One immediate instillation by itself has been shown to be insufficient treatment after TUR in patients with multiple tumors [3]; however, there is no consensus whether further intravesical chemotherapy or intra-vesical BCG should be given in these patients.…”

Section: Introductionmentioning

confidence: 99%

The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

2008

Self Cite

View full text Add to dashboard Cite

Objectives-Intravesical chemotherapy has been studied in randomized clinical trials for >30 yr; however, the optimal schedule and duration of treatment are unknown. The objective is to determine the effect of schedule and duration of intravesical chemotherapy on recurrence in patients with stage Ta T1 bladder cancer.Methods-A systematic review was conducted of the published results of randomized clinical trials that compared intravesical instillations with respect to their number, frequency, timing, duration, dose, or dose intensity.

show abstract

Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials

Cited by 2,515 publications

References 49 publications

Recurrence at Three Months and High-grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors

Recurrence at Three Months and High-grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors

The Application of Artificial Intelligence to Microarray Data: Identification of a Novel Gene Signature to Identify Bladder Cancer Progression

The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

Contact Info

Product

Resources

About